Skip to main content

Select Drug Profiles

Select Drug Profiles, Payers' Guide

Gazyva (Obinutuzumab) Approved as First-Line Treatment, with Chemotherapy, for Patients with Follicular Lymphoma

Lisa A. Raedler, PhD, RPh

Select Drug Profiles, Payers' Guide

Dysport (AbobotulinumtoxinA) Now FDA Approved for the Treatment of Lower-Limb Spasticity in Adults

Lisa A. Raedler, PhD, RPh

Select Drug Profiles, Payers' Guide

Dupixent (Dupilumab) First Biologic Drug Approved for Patients with Moderate-to-Severe Atopic Dermatitis

Lisa A. Raedler, PhD, RPh

Select Drug Profiles, Payers' Guide

Bavencio (Avelumab) Approved for Metastatic Merkel-Cell Carcinoma and for Urothelial Carcinoma

Lisa A. Raedler, PhD, RPh

Select Drug Profiles, Payers' Guide

Zejula (Niraparib) First PARP Inhibitor Approved for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Lisa A. Raedler, PhD, RPh

FDA Approvals, Select Drug Profiles

First FDA-Approved Test to Help Detect Several Leukemias and Lymphomas

FDA Approvals, Select Drug Profiles

First CAR T-Cell Therapy Unanimously Recommended by FDA Advisory Committee for Treatment of B-Cell ALL in Children and Young Adults

FDA Approvals, In the News, Select Drug Profiles

Rituximab Combination Now Approved in 3 Blood Cancers

FDA Approvals, Select Drug Profiles

Darzalex Combined with Pomalidomide and Dexamethasone Approved for Relapsed/Refractory Multiple Myeloma

FDA Approvals, Select Drug Profiles

Keytruda First Cancer Drug Approved for Any Solid Tumor Based on a Biomarker Instead of Tumor Site

10
11
12
13
14
15
16

Page 13 of 20
Results 121 - 130 of 200